Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month

[cafead]

via

• Demand is surging for weight-loss treatments that are being rolled out by major pharmaceutical companies.
• Investors are still trying to assess the full market opportunity and competitive landscape.
• It's important to recognize that these stocks' valuations have major implications for risk and potential returns.

article source